Introduction
============

Retinoblastoma (RB) is the most common ocular malignancy in infants and young children ([@b1-ol-0-0-9893]). Incidence of RB ranks second among all malignancies that occur in infants and young children. At present, the global incidence is about 1×6,000, and the number of new cases is about 5,000 per year ([@b2-ol-0-0-9893]). Statistics show that about 90% RB occurred before the age of 6, and more than 60% RB was monocular ([@b3-ol-0-0-9893]). In addition, the incidence was constant across race and region ([@b4-ol-0-0-9893]). RB seriously affects children\'s vision and even threatens their life. The key of the survival of RB patients is early diagnosis and timely effective treatment ([@b5-ol-0-0-9893]). According to literature, most patients with RB in China were diagnosed at advanced stages and the best time for non-surgical treatment is usually missed ([@b6-ol-0-0-9893]). However, the most common and effective treatment in clinical practice is surgical removal of diseased eyeballs ([@b7-ol-0-0-9893]).

Materials and methods
=====================

Since the internal organs of infants and young children are at the stage of growth and development, the functions of various systems are still immature. For example, they have a weak immune system and low sense of autonomy as well as ability to process outside information ([@b8-ol-0-0-9893]). According to literature, safety risks of general anesthesia in children undergoing surgery are much greater than in adults ([@b9-ol-0-0-9893]). Anesthetic agents have a pronounced impact on respiratory function in children. When children are sedated, their small airways are prone to collapse. Small airway closure leads to low lung ventilation, and children are prone to intraoperative complications such as cough, airway obstruction and even asphyxia ([@b10-ol-0-0-9893]). It was reported that dexmedetomidine (Dex) has strong calming and anti-anxiety effects while lacking respiratory depressant effects. It causes few adverse reactions, including a light impact on circulatory system. Dex is an excellent sedative and hypnotic drug and has been widely used in clinical anesthesia ([@b11-ol-0-0-9893]). To the best of our knowledge, there is no previous report on the effect of Dex on the respiratory system in pediatric patients undergoing RB surgical resection. This study aimed to investigate whether Dex can stabilize the respiratory function in perioperative children and can avoid complications such as arrhythmia and hypoxia caused by the surgical procedure.

### Subjects

A total of 87 pediatric patients who underwent RB resection were recruited into this study. General anesthesia was first induced for all patients, of which 45 were randomly assigned to the experimental group and received Dex through an intravenous infusion pump to maintain general anesthesia. In the experimental group, there were 24 males and 21 females, aged 1--8 years, with a mean age of 4.37±0.78 years. The remaining 42 patients were assigned to the control group and received saline through an intravenous infusion pump. In the control group, there were 22 males and 20 females, aged 1--8 years, with a mean age of 4.41±0.82 years. The general clinical records are shown in [Table I](#tI-ol-0-0-9893){ref-type="table"}.

Patients who met the following criteria were eligible for this study: i) patients who were assigned Class I or Class II according to American Society of Anesthesiologists (ASA) physical status classification ([@b12-ol-0-0-9893]); ii) patients who were diagnosed with RB by fundus examination and imaging tests such as B-ultrasound; and iii) patients who were assigned D-E phase, extraocular phase, and metastasis phase according to International Intraocular Retinoblastoma Classification (IIRC) ([@b12-ol-0-0-9893]), or patients who had extraocular RB or metastatic RB and experienced severe eye pain and whose lesioned eyeballs had no chance for recovery of vision. This study was approved by the Medical Ethics Committee of Yidu Central Hospital of Weifang (Weifang, China). Patients\' families were informed of the specific contents of the study and signed a completed informed consent form.

Patients who met the following criteria were excluded from the study: i) patients who suffered from primary disease affecting their respiratory function, such as bronchial asthma and myasthenia gravis; ii) patients who had cardiopulmonary disorders or liver/kidney dysfunction, associated with serious infection; and iii) patients who had obvious surgical contraindications such as coagulation disorders and allergy to anesthetic agents.

Methods
-------

### Pharmaceutical drugs and instruments

Pharmaceutical drugs used in this study were purchased from various sources: atropine sulfate injection \[SFDA Approval no. H41021817; Kaifeng Pharmaceutical (Group) Co., Ltd., Kaifeng, China\], phenobarbital tablets (SFDA Approval no. H61021669; Xi\'an Lijun Pharmaceutical Co., Ltd., Xi\'an, China), lidocaine hydrochloride injection (SFDA Approval no. H45020823; Guilin Pharmaceutical Co., Ltd., Guilin, China), sufentanil citrate injection (SFDA Approval no. H20054172; Yichang Humanwell Pharmaceutical Co., Ltd., Yichang, China), propofol injection (SFDA Approval no. H20123138; Jiangsu Nhwa Pharmaceutical Co., Ltd., Jiangsu, China) and Dex (SFDA Approval no. H20110086; Jiangsu Nhwa Pharmaceutical Co., Ltd.), midazolam (SFDA Approval no. ZWK-135-13791; Shanghai ZZBio Co., Ltd., Shanghai, China), and cisatracurium besylate \[SFDA Approval no. H20060926; DongYing (Jiangsu) Pharmaceutical Co., Ltd., Jiangsu, China\]. The following instruments were purchased from respective sources: the ECG monitor (Article no. 6800-10; Shanghai Zhiheng Medical Devices Co., Ltd., Shanghai, China) the tracheal intubation catheter (Article no. TK8976; Henan Zeyuan Medical Equipment Sales Co., Ltd., Beijing, China, <http://www.tdshoupin.com/>) and the anesthesia machine (Article no. 06; Beijing First Product Condar Technology Co., Ltd., Beijing, China).

### Anesthetic procedures

All pediatric patients underwent 8--12 h fasting and water-deprivation before surgery. Atropine sulfate (0.01 mg/kg) and phenobarbital tablets (2--3 mg/kg) were given via routine injection and oral administration, respectively, 30 min before entering the operating room to achieve preoperative stabilization. After the child entered the operating room, the surgical site was routinely disinfected before surgery. After performing local infiltration anesthesia by injection of 1% lidocaine, an indwelling catheter was placed on the right hand through radial artery puncture, followed by establishment of a venous access. Patients were then connected to an ECG monitor. A general anesthesia protocol was developed after assessment of the patient\'s overall physical state. The patient was gently pacified before anesthesia.

General anesthesia was induced for all subjects by intravenous injection of fentanyl (2.0--3.5 µg/kg), propofol (1.0--1.5 mg/kg), midazolam (0.05 mg/kg), and atracurium (0.5--0.8 mg/kg). During the same time, patients in the experimental group were given Dex (1 µg/kg) through an intravenous infusion pump at a rate of 0.2--0.8 µg/(kg•h) within 15 min, and patients in the control group received 0.9% saline (0.25 ml/kg) as a reference, through an intravenous infusion pump at a rate of 0.125 ml/(kg•h) within 15 min. After sufficient anesthetic depth was reached, tracheal intubation was performed to assist breathing using a catheter for age +18. After that, patient were connected to an anesthesia machine for breathing control. If the child still maintained spontaneous breathing function, expansion and contraction of the respiratory balloon, it could be seen with the breath. If spontaneous breathing was not observed, the anesthesia machine was then adjusted to provide a tidal volume of 14--20 ml/kg, a respiratory rate (R) of 20--30 breaths/min, an inspiration-to-expiration ratio (I:E) of 1:2, and an end-tidal CO~2~ partial pressure of 35--40 mmHg. During the operation, patients were checked regularly for a normal breath sound and a respiratory undulation of the chest.

### Observed indicators

i\) Indexes of respiratory function and hemodynamics at five time-points, i.e., before anesthesia induction (T0), 5 min after injection of anesthetic agents (T1), before intubation (T2), 15 min after intubation (T3), and 30 min after extubation (T4), were recorded for all subjects. The indexes of respiratory function included R and blood oxygen saturation (SpO~2~) value. The intraoperative hemodynamic indexes included heart rate (HR) and mean arterial pressure (MAP) value. ii) Incidence of perioperative cardiac and respiratory adverse events in both groups was recorded: cardiac arrest, apnea, bradycardia (HR was more than 30% lower than healthy children of the age group), tachycardia (HR was more than 30% higher than healthy children of the age group), vomiting, hypoxia (SpO~2~ \<90% at the end of 60 sec), and laryngism ([@b13-ol-0-0-9893],[@b14-ol-0-0-9893]). iii) Postoperative anesthesia recovery of the experimental and control groups was recorded in detail: recovery time of anesthesia (the time between discontinuation of intravenous anesthesia in the two groups to the blink of children) and the time of extubation (the time between discontinuation of intravenous anesthesia and organ catheter extraction). Agitation score (PAED) ([@b15-ol-0-0-9893]) was used to evaluate the postoperative agitation.

### Statistical analysis

Statistical analysis was performed using SPSS 19.0 statistics software system (IBM SPSS, Shanghai, China). Measurement data were expressed as mean ± standard deviation. The t-test was used for comparison between the two groups. Repeated measures ANOVA and Least Significant Difference post hoc test were used for comparison between multiple groups. Enumeration data were expressed in percentage (%). The χ^2^ test was used for the analysis of count data. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General clinical record

As shown in [Table I](#tI-ol-0-0-9893){ref-type="table"}, there were no significant differences in sex, age, and ASA classification between the experimental and control groups (P\>0.05).

### Respiratory rate (breaths/min) at different time-points

Regarding the comparison of R, there was no difference among T0-T4 in the experimental group (P\>0.05); there were differences among T0-T4 in the control group (P\<0.05). Compared with T0, the control group had a lower R at T2-T4 (P\<0.05). Compared with T1, the control group had a lower R at T2-T4 (P\<0.05). Compared with T2, the control group had a lower R at T3 and T4 (P\<0.05). Compared with the experimental group at the same time-point, R was higher at T2, and lower at T3 and T4 in the control group (P\<0.05), and no significant difference was found at T0 and T1 (P\>0.05; [Table II](#tII-ol-0-0-9893){ref-type="table"} and [Fig. 1](#f1-ol-0-0-9893){ref-type="fig"}).

### Blood oxygen saturation (SpO~2~) (%) at different time-points

SpO~2~ of the experimental group was slightly lower than that of T0 at T1-T4 (P\>0.05). Compared with T1, SpO~2~ of the experimental group decreased significantly at T3 (P\<0.05). Compared with T2, SpO~2~ of the experimental group decreased significantly at T3 (P\<0.05). Compared with T3, SpO~2~ of the experimental group decreased significantly at T4 (P\<0.05). In the control group, levels of SpO~2~ were significantly lower at T1-T4 than that at T0 (P\<0.05). Compared with the experimental group at the same time-point, SpO~2~ of the control group at T1-T4 decreased significantly (P\<0.05). Compared with T2, SpO~2~ of the control group decreased significantly at T3 (P\<0.05). Compared with T3, SpO~2~ of the control group decreased significantly at T4 (P\<0.05). Compared with the experimental group at the same time-point, SpO~2~ of the control group decreased significantly at T1-T4 (P\<0.05), and there was no significant difference between the two groups at T0 (P\>0.05; [Table III](#tIII-ol-0-0-9893){ref-type="table"} and [Fig. 2](#f2-ol-0-0-9893){ref-type="fig"}).

### HR (beats per minute) at different time-points

HR of the experimental group were lower at T3 and T4 than that at T0 (P\<0.05). HR of the experimental and control groups were lower at T1-T4 than that at T0 (P\<0.05). HR of the experimental group was higher than that of the control group at T1-T4 (P\<0.05). Compared with T1, HR of the control group decreased significantly at T3 and T4 (P\<0.05). Compared with T2, HR of the control group decreased significantly at T4 (P\<0.05). HR was higher in the experimental group than in the control group at T2-T4 (P\<0.05), but no significant differences were found at T0 and T1 (P\>0.05; [Table IV](#tIV-ol-0-0-9893){ref-type="table"} and [Fig. 3](#f3-ol-0-0-9893){ref-type="fig"}).

### MAP (mmHg) at different time-points

As shown in [Table V](#tV-ol-0-0-9893){ref-type="table"}, MAP of the experimental and control groups were lower at T1-T4 than that at T0 (P\<0.05). Compared with T1, MAP of the experimental group decreased at T3 and T4 (P\<0.05). Compared with T1, MAP of the control group decreased at T2-T4 (P\<0.05). Compared with T2, MAP of the control group decreased at T3 and T4 (P\<0.05). MAP of the control group was higher than that of the experimental group at T2 but lower than that of the experimental group at T1-T4, no significant differences were found at T0 ([Fig. 4](#f4-ol-0-0-9893){ref-type="fig"}).

### Post-anesthesia recovery in the two groups of children

The recovery time of the experimental and control groups were 8.37±4.93 and 8.63±4.74 min, respectively. There was no significant difference between the two groups (P\>0.05). The extubation time of the two groups was 10.48±4.72 and 10.74±4.13 min, respectively. There was no difference in the extubation time between the two groups (P\>0.05). Agitation scores of the two groups were 1.52±0.63 and 3.74±0.45, respectively. Agitation was more severe in the control group than in the experimental group (P\<0.05; [Fig. 5](#f5-ol-0-0-9893){ref-type="fig"}).

Discussion
==========

Since there is no universal screening for common eye diseases in newborns and preschool children in China, most RBs are diagnosed as advanced intraocular RB group D or above at diagnosis ([@b16-ol-0-0-9893]). Therefore, RB still poses a significant health threat to infants and young children in China. Currently, the clinical treatment of advanced RB is still the enucleation of the affected eyeball to avoid further progression of the disease ([@b17-ol-0-0-9893]). However, for infants and young children whose organ systems are not fully developed, conventional general anesthesia often has an inhibitory effect on respiratory function ([@b18-ol-0-0-9893]). For example, propofol is a widely used opioid analgesic in clinical practice with an excellent analgesic effect ([@b19-ol-0-0-9893]). However, propofol can decrease vagal tone, resulting in low extent of pulmonary expansion and collapse due to participation of vagus nerve in pulmonary stretch reflexes. Eventually the tidal volume decreases, and the respiratory function is suppressed ([@b20-ol-0-0-9893]). Another example is sufentanil, a strong opioid analgesic commonly used in clinical practice. It has the advantage of fast onset and short half-life ([@b21-ol-0-0-9893]). However, sufentanil has a strong affinity and selectivity for the µ receptors, which are distributed in the respiratory control center located in medulla oblongata, resulting in alterations in the heart rate and tidal volume. Eventually the respiratory function is affected ([@b22-ol-0-0-9893]).

Related studies showed that Dex is a highly selective α adrenergic receptor agonist. It has excellent anti-anxiety as well as strong analgesic and sedative effects ([@b23-ol-0-0-9893]). According to literature, Dex can reduce the output of sympathetic nerves by increasing the output of parasympathetic nerves, thereby inhibiting the activity of sympathetic nerves ([@b24-ol-0-0-9893]). The use of Dex during the surgical procedure, can reduce the fluctuation of hemodynamic parameters due to intraoperative events such as intubation, extubation, awakening and stress response, and also relieve the respiratory depression associated with the action of other drugs ([@b25-ol-0-0-9893]). To the best of our knowledge, there is no report in literature on the use of Dex in RB surgical resection and its effect on improving the respiratory function of pediatric patients with RB.

There were no significant differences in sex, age and ASA classification between the two groups. Patients in the experimental group received Dex. Their heart rates from T1 to T4 were all slightly lower than that at T0, but the differences were not statistically significant. Patients in the control group received saline, and their heart rate at T2 was significantly higher than that at T0 (P\<0.05), but the heart rates at T3 and T4 were all significantly lower than that at T0 (P\<0.05). Overall changes in heart rate in the control group were larger than those in the experimental group. In terms of SpO~2~, values from T1 to T4 in the experimental group fluctuated slightly compared with that at T0, but the differences were not statistically significant (P\>0.05). SpO~2~ values from T1 to T4 in the control group were significantly lower than that at T0 (P\<0.05), which was consistent with a trend demonstrated by large fluctuations of respiratory indexes in the control group. The intense and repeated tracheal stimulation resulted from tracheal intubation may cause fluctuations in the respiratory indexes. In the experimental group, however, the difference in the respiratory index between time-points T1 and T2 was not statistically significant, which suggested that Dex had a significant effect on relieving respiratory depression after the induction of general anesthesia. According to literature, the sedative effect of Dex does not impact spontaneous breathing ([@b26-ol-0-0-9893]). Dex exerts a mild analgesic effect and induces natural non-eye-movement sleep by agonizing α-adrenergic receptors in the brainstem locus coeruleus. Subjects in this sedated state can still be awakened ([@b27-ol-0-0-9893]). We think that this excitatory mechanism may not impact the vagal tone, and thus, it avoids the suppression signal from the respiratory control center in the medulla oblongata. In a word, Dex avoids perioperative respiratory depression from the port.

In terms of hemodynamics, our results showed that HR and MAP values from T1 to T4 were all lower than those at T0 in both the experimental and control groups. HR values in the experimental group were obviously higher than those at the same time-point in the control group. Compared with the control group, MAP value was lower at T2, but higher at T1-T4 in the experimental group. MAP values in the experimental group fluctuated within a smaller range compared with those in the control group, suggesting that Dex can counter abnormal decreases of heart rate and blood pressure caused by other drugs, thereby stabilizing hemodynamic parameters. According to literature, slow pump infusion of Dex can prevent activation of the q receptors located in the vascular smooth muscle, thereby relieving vasoconstriction ([@b28-ol-0-0-9893]). In addition, Dex can also counter abnormal increases of blood pressure and heart rate caused by stimulation of other drugs of the sympathetic nerves due to its inhibitory effect on sympathetic nerve activity ([@b29-ol-0-0-9893]). Our findings suggested that Dex can inhibit the release of catecholamines by acting on α receptors, thereby attenuating the physiological effects of catecholamines such as increases in myocardial contractility, cardiac stroke volume, and heart rate ([@b30-ol-0-0-9893]). In this way, Dex stabilizes intraoperative hemodynamics.

Analysis of post-anesthesia resuscitation showed no significant difference in both the recovery and extubation time between the two groups, but agitation was more severe in the control group than in the experimental group. Clinical studies have shown that children are often prone to anxiety and confusion after anesthesia. It has been reported that Dex can reduce the incidence of mental confusion in children ([@b31-ol-0-0-9893]). Compared with other commonly used sedative drugs such as Mita, Dex reduces the incidence of postoperative agitation in children ([@b32-ol-0-0-9893]). In the pediatric strabismus anesthesia for the same eye surgery, it has been reported that ([@b33-ol-0-0-9893]) intraoperative low-dose injection of Dex can reduce the frequency of fentanyl rescue, and the maximum value of intraoperative anxiety and discussion scores are smaller than those in the normal saline group. These studies have shown that Dex may significantly improve postoperative agitation in children.

In this study, the effect of Dex on respiratory function in pediatric patients undergoing RB resection was explored. In our future studies, interaction between multiple anesthetic sedatives will be considered. Animal models will also be established to explore the underlying mechanism. This study did not include the prognosis of respiratory function in children with RB, which should also be included in our future studies.

In summary, Dex can decrease surgical difficulties and increase anesthetic safety by improving the respiratory function and maintaining hemodynamic stability during anesthesia induction in children undergoing RB resection, so as to reduce surgical difficulty and increase anesthesia safety.
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![Respiratory rate (breaths/min) at different time-points. There were no significant differences in R value between different time-points in the experimental group (P\>0.05). In the control group, compared with T0 and T1, the R values were lower from T2 to T4 (P\<0.05); compared with T2, the R values were lower from T3 to T4 (P\<0.05). In the in-between-group comparison, the R values were comparable at T0 and T1 (P\>0.05), lower at T2 and higher from T3 to T4 (P\<0.05) in the experimental group. ^\#^P\<0.05, compared with the same time-point in the experimental group; ^a^P\<0.05, compared with T0 in the control group; ^b^P\<0.05, compared with T1 in the control group; ^c^P\<0.05, compared with T2 in the control group.](ol-17-03-2721-g00){#f1-ol-0-0-9893}

![Blood oxygen saturation (%) at different time-points. In the experimental group, the differences in SpO~2~ value were not statistically significant across the time-points (P\>0.05). In between-group comparison, the SpO~2~ values were all higher in the experimental group, and the difference at T2 was statistically significant (P\<0.05). ^\#^P\<0.05, compared with the same time-point in the experimental group; ^a^P\<0.05, compared with T0 in the experimental group; ^b^P\<0.05, compared with T1 in the experimental group; ^c^P\<0.05, compared with T2 in the experimental group; ^d^P\<0.05, compared with T3 in the experimental group; ^e^P\<0.05, compared with T0 in the control group; ^f^P\<0.05, compared with T1 in the control group; ^g^P\<0.05, compared with T2 in the control group; ^h^P\<0.05, compared with T3 in the control group.](ol-17-03-2721-g01){#f2-ol-0-0-9893}

![Heart rates (beats/min) at different time-points. In both the experimental and control groups, the HR values from T1 to T4 were all significantly lower compared with T0 (P\<0.05). In the in-between-group comparison, the HR values were all higher in the experimental group, and the differences were statistically significant (P\<0.05). ^\#^P\<0.05, compared with the same time-point in the experimental group; ^a^P\<0.05, compared with T0 in the experimental group; ^b^P\<0.05, compared with T0 in the control group; ^c^P\<0.05, compared with T1 in the control group; ^d^P\<0.05, compared with T2 in the control group.](ol-17-03-2721-g02){#f3-ol-0-0-9893}

![Mean arterial pressures (mmHg) at different time-points. In the experimental group, the MAP values from T1 to T4 were all lower than that at T0 (P\<0.05). In the in-between-group comparison, the MAP value was lower at T2 but higher at T1, T3 and T4 in the experimental group, and the differences were statistically significant (P\<0.05). ^\#^P\<0.05, compared with the same time-point in the experimental group; ^a^P\<0.05, compared with T0 in the experimental group; ^b^P\<0.05, compared with T1 in the experimental group; ^c^P\<0.05, compared with T0 in the control group; ^d^P\<0.05, compared with T1 in the control group; ^e^P\<0.05, compared with T2 in the control group.](ol-17-03-2721-g03){#f4-ol-0-0-9893}

![Comparison of post-anesthesia recovery in the two groups of children. There was no difference in extubation time between the two groups (p\>0.05). Agitation was more severe in the control group than in the experimental group (p\<0.05).](ol-17-03-2721-g04){#f5-ol-0-0-9893}

###### 

General clinical record (mean ± standard deviation) \[n (%)\].

  Variables                                               Experimental group n=45   Control group n=42   t or χ^2^   P-value
  ------------------------------------------------------- ------------------------- -------------------- ----------- ---------
  Age (year)                                              4.37±0.78                 4.41±0.82            0.233       0.816
  Body weight (kg)                                        8.59±5.37                 8.72±4.83            0.118       0.906
  Sex                                                                                                                
    Male                                                  24 (53.33)                22 (52.38)           0.008       0.929
    Female                                                21 (46.67)                20 (47.62)                       
  ASA classification                                                                                                 
    Class I                                               28 (62.22)                26 (61.90)           0.001       0.976
    Class II                                              17 (37.78)                16 (38.10)                       
  Clinical stage                                                                                                     
    Group D                                               21 (46.67)                18 (42.86)           0.470       0.926
    Group E                                               12 (26.67)                14 (33.33)                       
    Extraocular RB                                          7 (15.56)                 6 (14.29)                      
    Metastatic RB                                           5 (11.11)               4 (9.52)                         
  Clinical manifestation                                                                                             
    Strabismus                                              5 (11.11)                 5 (11.90)          0.077       0.995
    White pupillary reflex                                30 (66.67)                28 (66.67)                       
    Vision problem                                          5 (11.11)                 5 (11.90)                      
    Eye congestion                                          5 (11.11)               4 (9.52)                         
  Affected eye                                                                                                       
    Left eye                                              17 (37.78)                15 (35.71)           0.054       0.973
    Right eye                                             16 (35.55)                15 (35.71)                       
    Bilateral                                             12 (26.67)                12 (28.57)                       
  Three generations of immediate family members with RB                                                              
    Yes                                                   13 (28.89)                11 (26.19)           0.079       0.778
    No                                                    32 (71.11)                31 (73.81)                       

###### 

Respiratory rate (breaths/min) at different time-points.

  Time-points     Experimental group   Control group                                                                                            t       P-value
  --------------- -------------------- -------------------------------------------------------------------------------------------------------- ------- ----------
  T0              23.36±3.86           23.42±3.78                                                                                               0.073     0.942
  T1              23.28±3.97           21.83±2.86                                                                                               0.535     0.5938
  T2              22.67±4.24             25.46±3.35^[a](#tfn1-ol-0-0-9893){ref-type="table-fn"},[b](#tfn2-ol-0-0-9893){ref-type="table-fn"}^    3.389     0.001
  T3              23.32±4.15             18.68±2.13^[a](#tfn1-ol-0-0-9893){ref-type="table-fn"}--[c](#tfn3-ol-0-0-9893){ref-type="table-fn"}^   6.490   \<0.001
  T4              22.74±4.17             19.24±2.54^[a](#tfn1-ol-0-0-9893){ref-type="table-fn"}--[c](#tfn3-ol-0-0-9893){ref-type="table-fn"}^   4.687   \<0.001
  F~group~          8.298              −                                                                                                        −       −
  P~group~        \<0.001              −                                                                                                        −       −
  F~intercross~   21.311               −                                                                                                        −       −
  P~intercross~   \<0.001              −                                                                                                        −       −

P\<0.05, compared with T0 in the control group

P\<0.05, compared with T1 in the control group

P\<0.05, compared with T2 in the control group

###### 

Blood oxygen saturation (%) at different time-points.

  Time-points     Experimental group                                                                                       Control group                                                                                                                                        t         P-value
  --------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- --------- ---------
  T0              98.42±0.35                                                                                               98.36±0.41                                                                                                                                             0.736     0.464
  T1              98.36±0.29                                                                                                 97.34±0.26^[e](#tfn8-ol-0-0-9893){ref-type="table-fn"}^                                                                                            17.230    \<0.001
  T2              98.28±0.37                                                                                                 94.93±0.14^[e](#tfn8-ol-0-0-9893){ref-type="table-fn"},[f](#tfn9-ol-0-0-9893){ref-type="table-fn"}^                                                55.090    \<0.001
  T3                97.94±0.83^[a](#tfn4-ol-0-0-9893){ref-type="table-fn"}--[c](#tfn6-ol-0-0-9893){ref-type="table-fn"}^     96.15±0.21^[e](#tfn8-ol-0-0-9893){ref-type="table-fn"}--[g](#tfn10-ol-0-0-9893){ref-type="table-fn"}^                                              13.570    \<0.001
  T4                98.32±0.44^[d](#tfn7-ol-0-0-9893){ref-type="table-fn"}^                                                  95.02±0.14^[e](#tfn8-ol-0-0-9893){ref-type="table-fn"},[f](#tfn9-ol-0-0-9893){ref-type="table-fn"},[h](#tfn11-ol-0-0-9893){ref-type="table-fn"}^   46.450    \<0.001
  F~group~        82.000                                                                                                   −                                                                                                                                                    −         −
  P~group~        \<0.001                                                                                                  −                                                                                                                                                    −         −
  F~intercross~   82.000                                                                                                   −                                                                                                                                                    −         −
  P~intercross~   \<0.001                                                                                                  −                                                                                                                                                    −         −

P\<0.05, compared with T0 in the experimental group

P\<0.05, compared with T1 in the experimental group

P\<0.05, compared with T2 in the experimental group

P\<0.05, compared with T3 in the experimental group

P\<0.05, compared with T0 in the control group

P\<0.05, compared with T1 in the control group

P\<0.05, compared with T2 in the control group

P\<0.05, compared with T3 in the control group

###### 

Heart rates (beats/min) at different time-points.

  Time-points     Experimental group                                            Control group                                                                                               t       P-value
  --------------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------- ---------
  T0              127.52±8.74                                                   126.94±8.56                                                                                                 0.312     0.756
  T1              123.52±7.36                                                     121.43±6.35^[b](#tfn13-ol-0-0-9893){ref-type="table-fn"}^                                                 1.414     0.161
  T2              123.45±7.42                                                     118.93±6.14^[b](#tfn13-ol-0-0-9893){ref-type="table-fn"}^                                                 3.083     0.003
  T3                122.25±7.38^[a](#tfn12-ol-0-0-9893){ref-type="table-fn"}^     116.25±5.21^[b](#tfn13-ol-0-0-9893){ref-type="table-fn"},[c](#tfn14-ol-0-0-9893){ref-type="table-fn"}^    5.078   \<0.001
  T4                122.12±7.25^[a](#tfn12-ol-0-0-9893){ref-type="table-fn"}^     114.02±5.15^[b](#tfn13-ol-0-0-9893){ref-type="table-fn"}--[d](#tfn15-ol-0-0-9893){ref-type="table-fn"}^   5.969   \<0.001
  F~group~        27.461                                                        −                                                                                                           −       −
  P~group~        \<0.001                                                       −                                                                                                           −       −
  F~intercross~     1.528                                                       −                                                                                                           −       −
  P~intercross~     0.199                                                       −                                                                                                           −       −

P\<0.05, compared with T0 in the experimental group

P\<0.05, compared with T0 in the control group

P\<0.05, compared with T1 in the control group

P\<0.05, compared with T2 in the control group

###### 

Mean arterial pressure value (mmHg) at different time-points.

  Time-points   Experimental group                                                                                        Control group                                                                                              t       P-value
  ------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ------- ---------
  T0            70.67±4.83                                                                                                71.02±4.26                                                                                                 0.357     0.722
  T1              65.32±4.36^[a](#tfn16-ol-0-0-9893){ref-type="table-fn"}^                                                  63.43±3.35^[c](#tfn18-ol-0-0-9893){ref-type="table-fn"}^                                                 2.256     0.027
  T2              63.65±4.26^[a](#tfn16-ol-0-0-9893){ref-type="table-fn"}^                                                  68.55±3.24^[c](#tfn18-ol-0-0-9893){ref-type="table-fn"},[d](#tfn19-ol-0-0-9893){ref-type="table-fn"}^    6.006   \<0.001
  T3              62.25±4.72^[a](#tfn16-ol-0-0-9893){ref-type="table-fn"},[b](#tfn17-ol-0-0-9893){ref-type="table-fn"}^     60.13±3.16^[c](#tfn18-ol-0-0-9893){ref-type="table-fn"}--[e](#tfn20-ol-0-0-9893){ref-type="table-fn"}^   2.444     0.017
  T4              62.12±4.23^[a](#tfn16-ol-0-0-9893){ref-type="table-fn"},[b](#tfn17-ol-0-0-9893){ref-type="table-fn"}^     59.42±3.07^[c](#tfn18-ol-0-0-9893){ref-type="table-fn"}--[e](#tfn20-ol-0-0-9893){ref-type="table-fn"}^   3.387     0.001
  F             27.790                                                                                                    65.820                                                                                                             
  P-value       \<0.001                                                                                                   \<0.001                                                                                                            

P\<0.05, compared with T0 in the experimental group

P\<0.05, compared with T1 in the experimental group

P\<0.05, compared with T0 in the control group

P\<0.05, compared with T1 in the control group

P\<0.05, compared with T2 in the control group

[^1]: Contributed equally
